Market Overview

Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial

Share:
Related LLY
Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be
SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
European Ad Comm recommends approval of combo pill for type 2 diabetes (Seeking Alpha)

Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer's disease. In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild Alzheimer's disease, but not in patients with moderate Alzheimer's disease.

Posted-In: News FDA

 

Related Articles (LLY)

Around the Web, We're Loving...